John Mendlein

Track

Insider profile

Currently holds positions in aTyr Pharma Inc and Fate Therapeutics Inc

Performance

Overall performance
2.6
Performance over holding periods
2.6
30 days 90 days 120 days
Average return 10% 8.2% 15.1%
Success rate 96% 68% 82%
Transactions
3 67% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Director aTyr Pharma Inc Nov. 1, 2017 -
Vice Chairman of the Board Fate Therapeutics Inc Jan. 1, 2017 -
Independent Director Editas Medicine Inc Jan. 1, 2016 - March 27, 2018
Chief Executive Officer, Director aTyr Pharma Inc Dec. 1, 2015 - Nov. 1, 2017
Vice Chairman of the Board Fate Therapeutics Inc None -
Chief Executive Officer and Executive Chairman, Board of Directors aTyr Pharma Inc Sept. 1, 2011 - Dec. 1, 2015
John Mendlein's trades of Fate Therapeutics Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
297.61
Quantity 33,996
Value US$1,675,841
Transaction date
Purchase
Price
336.08
Quantity 23,714 -16.0%
Value US$3,186,301
Transaction date
Purchase
Price
295.50
Quantity 61,902 +19.5%
Value US$2,507,463
Transaction date
Planned sale
Price
35.48
Quantity 12,069 -7.0%
Value US$428,208
Transaction date
Planned sale
Price
34.73
Quantity 19,493 -10.2%
Value US$676,992
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-12-29 2025-12-24
PrS Proposed sale
33,996
297.61
US$1,675,841 		33,996 297.61 US$1,675,841
2023-01-13 2023-01-13
B Purchase
23,714 -16.0%
336.08
US$3,186,301 		23,714 -16.0% 336.08 US$3,186,301
2023-01-13 2023-01-11
B Purchase
61,902 +19.5%
295.50
US$2,507,463 		61,902 +19.5% 295.50 US$2,507,463
2022-06-06 2022-06-03
S Sale
1,364 -0.9%
22.79
US$31,086 		1,364 -0.9% 22.79 US$31,086
2022-03-11 2022-03-10
PlS Planned sale
12,069 -7.0%
35.48
US$428,208 		12,069 -7.0% 35.48 US$428,208
2022-03-11 2022-03-10
PlS Planned sale
19,493 -10.2%
34.73
US$676,992 		19,493 -10.2% 34.73 US$676,992